{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:35:21Z","timestamp":1789464921953,"version":"build-2803163510"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Dis Travel Med Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The substantial number of older adults undertaking international travel has increased the relevance of pre-travel prevention in this population. However, vaccination strategies in this group require consideration of immune aging, baseline status, medication use, and travel-related exposure. This narrative review summarizes the current evidence on vaccination in senior travelers, with particular attention to the vaccines most relevant to this population, the differences in the strength of evidence across vaccines, and the clinical factors that should guide pre-travel decision-making. Routine vaccines, including influenza, COVID-19, pneumococcal, respiratory syncytial virus, herpes zoster, and tetanus-diphtheria vaccines, constitute an essential part of pre-travel assessment, whereas travel-specific vaccines, such as hepatitis A, hepatitis B, typhoid, rabies, Japanese encephalitis, tick-borne encephalitis, and cholera, should be considered according to the destination, itinerary, expected exposure, and time before departure. Yellow fever vaccination represents a particular clinical challenge because advancing age is associated with a greater risk of serious vaccine-associated adverse events, making individualized risk\u2012benefit assessment essential. Recently introduced dengue and chikungunya vaccines should also be considered on an individualized basis, taking into account exposure risk, potential benefits, comorbidities, and the current limitations of the available evidence. The review also highlights the importance of integrating vaccination with non-vaccine preventive strategies, including food and water precautions, vector avoidance, and hygiene measures. Although the evidence base has expanded, important uncertainties remain, particularly because age-specific data are limited and frail older adults remain underrepresented in clinical studies. Overall, pre-travel care for senior travelers should be comprehensive, exposure-based, and individualized according to the clinical profile and travel characteristics of each traveler.<\/jats:p>","DOI":"10.1186\/s40794-026-00315-1","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:43:24Z","timestamp":1789400604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Travel vaccination in senior travelers: current evidence, challenges, and prevention"],"prefix":"10.1186","volume":"12","author":[{"given":"Andrea","family":"Rossanese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tomasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"315_CR1","unstructured":"Eurostat. Tourism trends and ageing [Internet]. Luxembourg: Publications Office of the European Union. 2024. Available from: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/."},{"key":"315_CR2","doi-asserted-by":"publisher","unstructured":"Choi-Allum LAARP, [Internet]., Washington DC, [cited 2026 Jul 7]. Soaring into 2025: Travel Plans Take Flight Among 50-Plus Travelers. Available from: https:\/\/doi.org\/10.26419\/res.00882.001.","DOI":"10.26419\/res.00882.001"},{"issue":"3","key":"315_CR3","doi-asserted-by":"publisher","first-page":"taag011","DOI":"10.1093\/jtm\/taag011","volume":"33","author":"M Arsuaga","year":"2026","unstructured":"Arsuaga M, Oliveira-Souto I, S\u00e1nchez-Montalv\u00e1 A, De La Calle-Prieto F, Pou D, Chamorro-Tojeiro S, et al. Travel health risks in adults over 60 years of age: insights from the +Redivi network in Spain. J Travel Med. 2026;33(3):taag011. https:\/\/doi.org\/10.1093\/jtm\/taag011.","journal-title":"J Travel Med"},{"issue":"1","key":"315_CR4","doi-asserted-by":"publisher","first-page":"taaa216","DOI":"10.1093\/jtm\/taaa216","volume":"28","author":"JA Vlot","year":"2021","unstructured":"Vlot JA, Vive MGD, Brockhoff HJ, Van Genderen PJJ, Trompenaars MCE, Van Steenbergen JE, et al. Predicting morbidity in older travellers during a short-term stay in the tropics: the ELDEST study. J Travel Med. 2021;28(1):taaa216. https:\/\/doi.org\/10.1093\/jtm\/taaa216.","journal-title":"J Travel Med"},{"issue":"1","key":"315_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/10806032241245399","volume":"36","author":"MS Badger","year":"2025","unstructured":"Badger MS. The Intersection of Geriatrics, Climate Change, and Wilderness Medicine: Education is Critical. Wilderness Environ Med. 2025;36(1):27\u201334. https:\/\/doi.org\/10.1177\/10806032241245399.","journal-title":"Wilderness Environ Med"},{"issue":"6","key":"315_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tmaid.2015.10.001","volume":"13","author":"VK Jaeger","year":"2015","unstructured":"Jaeger VK, Tschudi N, R\u00fcegg R, Hatz C, B\u00fchler S. The elderly, the young and the pregnant traveler -- A retrospective data analysis from a large Swiss Travel Center with a special focus on malaria prophylaxis and yellow fever vaccination. Travel Med Infect Dis. 2015;13(6):475\u201384. https:\/\/doi.org\/10.1016\/j.tmaid.2015.10.001.","journal-title":"Travel Med Infect Dis"},{"issue":"6","key":"315_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/vaccines13060643","volume":"13","author":"R Niyati","year":"2025","unstructured":"Niyati R, Rezahosseini O, Ekenberg C, Larsen CS, Harboe ZB. Immunogenicity and Safety of Pneumococcal Vaccines Co-Administered with Common Travel Vaccines in Adults: A Systematic Review. Vaccines. 2025;13(6):643. https:\/\/doi.org\/10.3390\/vaccines13060643.","journal-title":"Vaccines"},{"issue":"1","key":"315_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40794-017-0054-0","volume":"3","author":"TK Lee","year":"2017","unstructured":"Lee TK, Hutter JN, Masel J, Joya C, Whitman TJ. Guidelines for the prevention of travel-associated illness in older adults. Trop Dis Travel Med Vaccines. 2017;3(1):10. https:\/\/doi.org\/10.1186\/s40794-017-0054-0.","journal-title":"Trop Dis Travel Med Vaccines"},{"issue":"7","key":"315_CR9","doi-asserted-by":"publisher","first-page":"taaa006","DOI":"10.1093\/jtm\/taaa006","volume":"27","author":"L Furuya-Kanamori","year":"2020","unstructured":"Furuya-Kanamori L, Ramsey L, Manson M, Gilbert B, Lau CL. Intradermal rabies pre-exposure vaccination schedules in older travellers: comparison of immunogenicity post-primary course and post-booster. J Travel Med. 2020;27(7): https:\/\/doi.org\/10.1093\/jtm\/taaa006.","journal-title":"J Travel Med"},{"issue":"4","key":"315_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ijpp\/riae024","volume":"32","author":"L Goodyer","year":"2024","unstructured":"Goodyer L, Evans D, Wilson A, Palit P, Ma C, Lister HR, et al. Experiences of community pharmacists in the United Kingdom on the provision of travel health services and associated educational requirements. Int J Pharm Pract. 2024;32(4):287\u201393. https:\/\/doi.org\/10.1093\/ijpp\/riae024.","journal-title":"Int J Pharm Pract"},{"issue":"5","key":"315_CR11","doi-asserted-by":"publisher","first-page":"taab059","DOI":"10.1093\/jtm\/taab059","volume":"28","author":"DJ Mills","year":"2021","unstructured":"Mills DJ, Lau CL, Mills C, Furuya-Kanamori L. Efficacy of one-dose intramuscular rabies vaccine as pre-exposure prophylaxis in travellers. J Travel Med. 2021;28(5):taab059. https:\/\/doi.org\/10.1093\/jtm\/taab059.","journal-title":"J Travel Med"},{"key":"315_CR12","doi-asserted-by":"publisher","first-page":"128251","DOI":"10.1016\/j.vaccine.2026.128251","volume":"75","author":"K Kling","year":"2026","unstructured":"Kling K, Falman A, Branke L, Ramharter M, Rothe C, Sch\u00f6nfeld C, et al. Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya. Vaccine. 2026;75:128251. https:\/\/doi.org\/10.1016\/j.vaccine.2026.128251.","journal-title":"Vaccine"},{"issue":"10267","key":"315_CR13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2020","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet. 2020;396(10267):1979\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(20)32466-1.","journal-title":"Lancet"},{"issue":"5","key":"315_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.tmaid.2014.05.004","volume":"12","author":"RW Wieten","year":"2014","unstructured":"Wieten RW, Van Der Schalie M, Visser BJ, Grobusch MP, Van Vugt M. Risk factors and pre-travel healthcare of international travellers attending a Dutch travel clinic: A cross-sectional analysis. Travel Med Infect Dis. 2014;12(5):511\u201324. https:\/\/doi.org\/10.1016\/j.tmaid.2014.05.004.","journal-title":"Travel Med Infect Dis"},{"key":"315_CR15","doi-asserted-by":"publisher","unstructured":"Hochberg NS, Barnett ED, Chen LH, Wilson ME, Iyer H, MacLeod WB et al. International travel by persons With medical comorbidities: understanding risks and providing advice. Mayo Clin Proc. 2013;88(11):1231\u201340. https:\/\/doi.org\/10.1016\/j.mayocp.2013.07.018.","DOI":"10.1016\/j.mayocp.2013.07.018"},{"issue":"5\u20136","key":"315_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.tmaid.2012.09.004","volume":"10","author":"C Aubry","year":"2012","unstructured":"Aubry C, Gaudart J, Gaillard C, Delmont J, Parola P, Brouqui P, et al. Demographics, health and travel characteristics of international travellers at a pre-travel clinic in Marseille, France. Travel Med Infect Dis. 2012;10(5\u20136):247\u201356. https:\/\/doi.org\/10.1016\/j.tmaid.2012.09.004.","journal-title":"Travel Med Infect Dis"},{"issue":"10","key":"315_CR17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.3390\/microorganisms12102052","volume":"12","author":"N Theodorakis","year":"2024","unstructured":"Theodorakis N, Feretzakis G, Hitas C, Kreouzi M, Kalantzi S, Spyridaki A, et al. Immunosenescence: How Aging Increases Susceptibility to Bacterial Infections and Virulence Factors. Microorganisms. 2024;12(10):2052. https:\/\/doi.org\/10.3390\/microorganisms12102052. PubMed PMID: 39458361; PubMed Central PMCID: PMC11510421.","journal-title":"Microorganisms"},{"issue":"52","key":"315_CR18","doi-asserted-by":"publisher","first-page":"8264","DOI":"10.1016\/j.vaccine.2020.11.002","volume":"38","author":"JC Allen","year":"2020","unstructured":"Allen JC, Toapanta FR, Chen W, Tennant SM. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine. 2020;38(52):8264\u201372. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.002. PubMed PMID: 33229108; PubMed Central PMCID: PMC7719605.","journal-title":"Vaccine"},{"key":"315_CR19","doi-asserted-by":"publisher","unstructured":"D\u2019Acremont V, Herzog C, Genton B. Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal\u00ae in the Elderly. J Travel Med. 2006;13(2):78\u201383. https:\/\/doi.org\/10.1111\/j.1708-8305.2006.00001.x.","DOI":"10.1111\/j.1708-8305.2006.00001.x"},{"key":"315_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000504491","volume":"43","author":"A Kwetkat","year":"2020","unstructured":"Kwetkat A, Heppner HJ. Comorbidities in the Elderly and Their Possible Influence on Vaccine Response. Interdiscip Top Gerontol Geriatr. 2020;43:73\u201385. https:\/\/doi.org\/10.1159\/000504491. PubMed PMID: 32305984.","journal-title":"Interdiscip Top Gerontol Geriatr"},{"issue":"24","key":"315_CR21","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1097\/CM9","volume":"137","author":"R Chen","year":"2024","unstructured":"Chen R, Zou J, Chen J, Wang L, Kang R, Tang D. Immune aging and infectious diseases. Chin Med J (Engl). 2024;137(24):3010\u201349. https:\/\/doi.org\/10.1097\/CM9. 0000000000003410 PubMed PMID: 39679477; PubMed Central PMCID: PMC11706578.","journal-title":"Chin Med J (Engl)"},{"key":"315_CR22","doi-asserted-by":"publisher","unstructured":"Turner DP, McGuinness SL, Cohen J, Waring LJ, Leder K. Use of pre-travel vaccine-preventable disease serology as a screening tool to identify patients in need of pre-travel vaccination: a retrospective audit. J Travel Med. 2017;24(3). https:\/\/doi.org\/10.1093\/jtm\/tax011. PubMed PMID: 28355621.","DOI":"10.1093\/jtm\/tax011"},{"issue":"12","key":"315_CR23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jiac.2023.08.013","volume":"29","author":"K Yamamoto","year":"2023","unstructured":"Yamamoto K, Asai Y, Nakagawa H, Nakatani I, Hayashi K, Matono T, et al. Characteristics of preventive intervention acceptance for international travel among clients aged 60 years and older from a Japanese multicenter pretravel consultation registry. J Infect Chemother. 2023;29(12):1137\u201344. https:\/\/doi.org\/10.1016\/j.jiac.2023.08.013.","journal-title":"J Infect Chemother"},{"key":"315_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tmaid.2017.07.006","volume":"19","author":"M Van Aalst","year":"2017","unstructured":"Van Aalst M, Verhoeven R, Omar F, Stijnis C, Van Vugt M, De Bree GJ, et al. Pre-travel care for immunocompromised and chronically ill travellers: A retrospective study. Travel Med Infect Dis. 2017;19:37\u201348. https:\/\/doi.org\/10.1016\/j.tmaid.2017.07.006.","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"315_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.idc.2012.07.003","volume":"26","author":"A Matteelli","year":"2012","unstructured":"Matteelli A, Carvalho ACC, Bigoni S. Visiting relatives and friends (VFR), pregnant, and other vulnerable travelers. Infect Dis Clin North Am. 2012;26(3):625\u201335. https:\/\/doi.org\/10.1016\/j.idc.2012.07.003. PubMed PMID: 22963774.","journal-title":"Infect Dis Clin North Am"},{"key":"315_CR26","doi-asserted-by":"publisher","unstructured":"Whitaker JA. Immunization Strategies to Span the Spectrum of Immunocompromised Adults. Mayo Clin Proc. 2020;95(7):1530\u201348. https:\/\/doi.org\/10.1016\/j.mayocp.201909.002 PubMed PMID: 32067801.","DOI":"10.1016\/j.mayocp.201909.002"},{"issue":"4","key":"315_CR27","doi-asserted-by":"publisher","first-page":"taad056","DOI":"10.1093\/jtm\/taad056","volume":"30","author":"SL McGuinness","year":"2023","unstructured":"McGuinness SL, Eades O, Seale H, Cheng AC, Leder K. Pre-travel vaccine information needs, attitudes, drivers of uptake and the role for decision aids in travel medicine. J Travel Med. 2023;30(4):taad056. https:\/\/doi.org\/10.1093\/jtm\/taad056. PubMed PMID: 37074157; PubMed Central PMCID: PMC10289516.","journal-title":"J Travel Med"},{"issue":"4","key":"315_CR28","doi-asserted-by":"publisher","first-page":"937","DOI":"10.4269\/ajtmh.22-0633","volume":"109","author":"E Rapheal","year":"2023","unstructured":"Rapheal E, Prithviraj R, Campbell S, Stoddard ST, Paz-Soldan VA. Using the Health Belief Model to Predict Pre-Travel Health Decisions among U.S.-Based Travelers. Am J Trop Med Hyg. 2023;109(4):937\u201344. https:\/\/doi.org\/10.4269\/ajtmh.22-0633.","journal-title":"Am J Trop Med Hyg"},{"key":"315_CR29","doi-asserted-by":"publisher","first-page":"677907","DOI":"10.3389\/fragi.2021.677907","volume":"2","author":"F Ecarnot","year":"2021","unstructured":"Ecarnot F, Maggi S, Michel JP, Veronese N, Rossanese A. Vaccines and Senior Travellers. Front Aging. 2021;2:677907. https:\/\/doi.org\/10.3389\/fragi.2021.677907.","journal-title":"Front Aging"},{"issue":"4","key":"315_CR30","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s12325-023-02432-1","volume":"40","author":"J Langer","year":"2023","unstructured":"Langer J, Welch VL, Moran MM, Cane A, Lopez SMC, Srivastava A, et al. High Clinical Burden of Influenza Disease in Adults Aged\u2009\u2265\u200965 Years: Can We Do Better? A Systematic Literature Review. Adv Ther. 2023;40(4):1601\u201327. https:\/\/doi.org\/10.1007\/s12325-023-02432-1.","journal-title":"Adv Ther"},{"issue":"1","key":"315_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40266-018-0597-4","volume":"36","author":"MK Andrew","year":"2019","unstructured":"Andrew MK, Bowles SK, Pawelec G, Haynes L, Kuchel GA, McNeil SA, et al. Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications. Drugs Aging. 2019;36(1):29\u201337. https:\/\/doi.org\/10.1007\/s40266-018-0597-4.","journal-title":"Drugs Aging"},{"issue":"3","key":"315_CR32","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.12771\/emj.2024.e35","volume":"47","author":"JY Song","year":"2024","unstructured":"Song JY. Influenza disease burden and the need for highly immunogenic vaccines in older adults: a narrative review. Ewha Med J. 2024;47(3):e35. https:\/\/doi.org\/10.12771\/emj.2024.e35.","journal-title":"Ewha Med J"},{"key":"315_CR33","doi-asserted-by":"publisher","first-page":"100327","DOI":"10.1016\/j.jvacx.2023.100327","volume":"14","author":"JKH Lee","year":"2023","unstructured":"Lee JKH, Lam GKL, Yin JK, Loiacono MM, Samson SI. High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update. Vaccine: X. 2023;14:100327. https:\/\/doi.org\/10.1016\/j.jvacx.2023.100327.","journal-title":"Vaccine: X"},{"issue":"1","key":"315_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12979-017-0107-2","volume":"15","author":"B Weinberger","year":"2018","unstructured":"Weinberger B. Vaccines for the elderly: current use and future challenges. Immun Ageing. 2018;15(1):3. https:\/\/doi.org\/10.1186\/s12979-017-0107-2.","journal-title":"Immun Ageing"},{"issue":"3","key":"315_CR35","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s11739-023-03456-9","volume":"19","author":"R Antonelli Incalzi","year":"2024","unstructured":"Antonelli Incalzi R, Consoli A, Lopalco P, Maggi S, Sesti G, Veronese N, et al. Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion. Intern Emerg Med. 2024;19(3):619\u201340. https:\/\/doi.org\/10.1007\/s11739-023-03456-9.","journal-title":"Intern Emerg Med"},{"key":"315_CR36","doi-asserted-by":"publisher","first-page":"1113156","DOI":"10.3389\/fimmu.2023.1113156","volume":"14","author":"K Xu","year":"2023","unstructured":"Xu K, Wang Z, Qin M, Gao Y, Luo N, Xie W, et al. A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults. Front Immunol. 2023;14:1113156. https:\/\/doi.org\/10.3389\/fimmu.2023.1113156.","journal-title":"Front Immunol"},{"issue":"25","key":"315_CR37","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383(25):2427\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2028436.","journal-title":"N Engl J Med"},{"key":"315_CR38","doi-asserted-by":"publisher","first-page":"104405","DOI":"10.1016\/j.tourman.2021.104405","volume":"88","author":"C Suess","year":"2022","unstructured":"Suess C, Maddock JE, Dogru T, Mody M, Lee S. Using the Health Belief Model to examine travelers\u2019 willingness to vaccinate and support for vaccination requirements prior to travel. Tour Manag. 2022;88:104405. https:\/\/doi.org\/10.1016\/j.tourman.2021.104405.","journal-title":"Tour Manag"},{"issue":"10379","key":"315_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0140-6736(22)02465-5","volume":"401","author":"C Stein","year":"2023","unstructured":"Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023;401(10379):833\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(22)02465-5.","journal-title":"Lancet"},{"issue":"5","key":"315_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"N Engl J Med"},{"issue":"12","key":"315_CR41","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","volume":"9","author":"SM Hsieh","year":"2021","unstructured":"Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, et al. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respiratory Med. 2021;9(12):1396\u2013406. https:\/\/doi.org\/10.1016\/S2213-2600(21)00402-1.","journal-title":"Lancet Respiratory Med"},{"issue":"1","key":"315_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41479-017-0045-y","volume":"10","author":"P Van Buynder","year":"2018","unstructured":"Van Buynder P, Booy R. Pneumococcal vaccination in older persons: where are we today? Pneumonia. 2018;10(1):1. https:\/\/doi.org\/10.1186\/s41479-017-0045-y.","journal-title":"Pneumonia"},{"issue":"26","key":"315_CR43","doi-asserted-by":"publisher","first-page":"126390","DOI":"10.1016\/j.vaccine.2024.126390","volume":"42","author":"MA Fletcher","year":"2024","unstructured":"Fletcher MA, Vojicic J, Daigle D, Taysi B, Haridy H, Abalos MG, et al. National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific. Vaccine. 2024;42(26):126390. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126390.","journal-title":"Vaccine"},{"issue":"12","key":"315_CR44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","volume":"372","author":"MJM Bonten","year":"2015","unstructured":"Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med. 2015;372(12):1114\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1408544.","journal-title":"N Engl J Med"},{"issue":"2","key":"315_CR45","doi-asserted-by":"publisher","first-page":"ofaf069","DOI":"10.1093\/ofid\/ofaf069","volume":"12","author":"T Ngamprasertchai","year":"2025","unstructured":"Ngamprasertchai T, Ruenroengbun N, Kajeekul R. Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Open Forum Infect Dis. 2025;12(2):ofaf069. https:\/\/doi.org\/10.1093\/ofid\/ofaf069.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"315_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","volume":"74","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi M, Leidner AJ, Gierke R, Xing W, Accorsi E, Moro P, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged\u2009\u2265\u200950 Years: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7401a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"178","key":"315_CR47","doi-asserted-by":"publisher","first-page":"250016","DOI":"10.1183\/16000617.0016-2025","volume":"34","author":"G Sotgiu","year":"2025","unstructured":"Sotgiu G, Puci M, Bartoletti M, Blasi F, Bonanni P, Aliberti S. Recommendations on PCV20 vaccine in adults and at-risk populations. Eur Respir Rev. 2025;34(178):250016. https:\/\/doi.org\/10.1183\/16000617.0016-2025.","journal-title":"Eur Respir Rev"},{"issue":"5","key":"315_CR48","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s41999-024-01066-y","volume":"15","author":"AC Moreira","year":"2024","unstructured":"Moreira AC, Ribeiro AB, Oliveira I, S\u00e1 M, Lameir\u00e3o C, Marques P. Efficacy of anti-RSV vaccination in preventing respiratory syncytial virus disease and severe illness in older adults: a systematic review of randomized controlled trials. Eur Geriatr Med. 2024;15(5):1215\u201329. https:\/\/doi.org\/10.1007\/s41999-024-01066-y.","journal-title":"Eur Geriatr Med"},{"key":"315_CR49","doi-asserted-by":"publisher","first-page":"100397","DOI":"10.1016\/j.jvacx.2023.100397","volume":"15","author":"R Zeevaert","year":"2023","unstructured":"Zeevaert R, Thiry N, De Maertens C, Roberfroid D. Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis. Vaccine: X. 2023;15:100397. https:\/\/doi.org\/10.1016\/j.jvacx.2023.100397.","journal-title":"Vaccine: X"},{"issue":"4","key":"315_CR50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5694\/mja2.52389","volume":"221","author":"AJ Hendry","year":"2024","unstructured":"Hendry AJ, Quinn HE, Macartney K, Beard FH. Tetanus, pertussis, and diphtheria vaccination coverage in older adults, Australia, 2023: analysis of Australian Immunisation Register data. Med J Aust. 2024;221(4):224\u20135. https:\/\/doi.org\/10.5694\/mja2.52389.","journal-title":"Med J Aust"},{"key":"315_CR51","doi-asserted-by":"crossref","unstructured":"Weinberger B. Vaccination of Adults and the older population against Tetanus, Diphtheria, Pertussis, and Tick-Borne Encephalitis: The importance of booster vaccinations throughout Life. 2020;43.","DOI":"10.1159\/000504489"},{"issue":"42","key":"315_CR52","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1016\/j.vaccine.2015.08.068","volume":"33","author":"S Karki","year":"2015","unstructured":"Karki S, McIntyre P, Newall AT, MacIntyre CR, Banks E, Liu B. Risk factors for pertussis hospitalizations in Australians aged 45 years and over: A population based nested case\u2013control study. Vaccine. 2015;33(42):5647\u201353. https:\/\/doi.org\/10.1016\/j.vaccine.2015.08.068.","journal-title":"Vaccine"},{"issue":"1","key":"315_CR53","doi-asserted-by":"publisher","first-page":"2160600","DOI":"10.1080\/21645515.2022.2160600","volume":"19","author":"CA Robertson","year":"2023","unstructured":"Robertson CA, Jacqmein J, Selmani A, Galarza K, Oster P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged\u2009\u2265\u200959 years: A phase III randomized study. Hum Vaccines Immunotherapeutics. 2023;19(1):2160600. https:\/\/doi.org\/10.1080\/21645515.2022.2160600.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"3","key":"315_CR54","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40121-025-01298-w","volume":"15","author":"GS Dbaibo","year":"2026","unstructured":"Dbaibo GS, Balik I, Akdemir \u0130, Buzgan T, Guner R, Boutros CF, et al. Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj\/Umrah Pilgrims Aged\u2009\u2265\u200956 Years: A Phase III, Open-Label Study. Infect Dis Ther. 2026;15(3):769\u201385. https:\/\/doi.org\/10.1007\/s40121-025-01298-w.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"315_CR55","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1080\/21645515.2020.1819742","volume":"17","author":"C Herzog","year":"2021","unstructured":"Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects \u2013 a review of the evidence. Hum Vaccines Immunotherapeutics. 2021;17(5):1496\u2013519. https:\/\/doi.org\/10.1080\/21645515.2020.1819742.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"5","key":"315_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6905a1","volume":"69","author":"NP Nelson","year":"2020","unstructured":"Nelson NP, Weng MK, Hofmeister MG, Moore KL, Doshani M, Kamili S, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69(5):1\u201338. https:\/\/doi.org\/10.15585\/mmwr.rr6905a1.","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"315_CR57","doi-asserted-by":"publisher","first-page":"taac013","DOI":"10.1093\/jtm\/taac013","volume":"29","author":"O Balogun","year":"2022","unstructured":"Balogun O, Brown A, Angelo KM, Hochberg NS, Barnett ED, Nicolini LA, et al. Acute hepatitis A in international travellers: a GeoSentinel analysis, 2008\u20132020. J Travel Med. 2022;29(2):taac013. https:\/\/doi.org\/10.1093\/jtm\/taac013.","journal-title":"J Travel Med"},{"issue":"19","key":"315_CR58","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.vaccine.2013.03.011","volume":"31","author":"Pjun Lu","year":"2013","unstructured":"Lu Pjun, Byrd KK, Murphy TV. Hepatitis A vaccination coverage among adults 18\u201349 years traveling to a country of high or intermediate endemicity, United States. Vaccine. 2013;31(19):2348\u201357. https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.011.","journal-title":"Vaccine"},{"issue":"5","key":"315_CR59","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1708-8305.2009.00320.x","volume":"16","author":"L Costas","year":"2009","unstructured":"Costas L, Vilella A, Trilla A, Serrano B, Vera I, Rold\u00e1n M, et al. Vaccination Strategies Against Hepatitis A in Travelers Older Than 40 Years: An Economic Evaluation. J Travel Med. 2009;16(5):344\u20138. https:\/\/doi.org\/10.1111\/j.1708-8305.2009.00320.x.","journal-title":"J Travel Med"},{"issue":"43","key":"315_CR60","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.15585\/mmwr.mm6743a5","volume":"67","author":"NP Nelson","year":"2018","unstructured":"Nelson NP, Link-Gelles R, Hofmeister MG, Romero JR, Moore KL, Ward JW, et al. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR Morb Mortal Wkly Rep. 2018;67(43):1216\u201320. https:\/\/doi.org\/10.15585\/mmwr.mm6743a5.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"315_CR61","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.vaccine.2023.01.007","volume":"41","author":"V Tricou","year":"2023","unstructured":"Tricou V, Eyre S, Ramjee M, Collini P, Mojares Z, Loeliger E, et al. A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. Vaccine. 2023;41(7):1398\u2013407. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.007.","journal-title":"Vaccine"},{"issue":"12","key":"315_CR62","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.cmi.2023.08.006","volume":"29","author":"M Riekkinen","year":"2023","unstructured":"Riekkinen M, Pakkanen SH, Hutse V, Roukaerts I, Ollgren J, K\u00e4yhty H, et al. Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial. Clin Microbiol Infect. 2023;29(12):1553\u201360. https:\/\/doi.org\/10.1016\/j.cmi.2023.08.006.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"315_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12979-020-00179-9","volume":"17","author":"R Edelman","year":"2020","unstructured":"Edelman R, Deming ME, Toapanta FR, Heuser MD, Chrisley L, Barnes RS, et al. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immun Ageing. 2020;17(1):9. https:\/\/doi.org\/10.1186\/s12979-020-00179-9.","journal-title":"Immun Ageing"},{"issue":"25\u201326","key":"315_CR64","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1016\/S0264-410X(03)00399-2","volume":"21","author":"B Wolters","year":"2003","unstructured":"Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine. 2003;21(25\u201326):3623\u20138. https:\/\/doi.org\/10.1016\/S0264-410X(03)00399-2.","journal-title":"Vaccine"},{"issue":"11","key":"315_CR65","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1086\/344271","volume":"35","author":"DN Fisman","year":"2002","unstructured":"Fisman DN, Agrawal D, Leder K. The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta-analysis. CLIN INFECT DIS. 2002;35(11):1368\u201375. https:\/\/doi.org\/10.1086\/344271.","journal-title":"CLIN INFECT DIS"},{"issue":"S1","key":"315_CR66","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1572-0241.2006.00469.x","volume":"101","author":"TL Wright","year":"2006","unstructured":"Wright TL. Introduction to Chronic Hepatitis B Infection. Am J Gastroenterol. 2006;101(S1):S1\u20136. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00469.x.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"315_CR67","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/vaccines11030597","volume":"11","author":"LR Da Cunha Rosa","year":"2023","unstructured":"Da Cunha Rosa LR, Brand\u00e3o LGVA, Moura W\u00c9A, Campos LR, Pessoni GC, De Oliveira Roque E, Lima J, et al. Prevalence, Risk Factors and Vaccine Response against Hepatitis B in People Aged 50 Years or Older. Vaccines. 2023;11(3):597. https:\/\/doi.org\/10.3390\/vaccines11030597.","journal-title":"Vaccines"},{"issue":"3","key":"315_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","volume":"70","author":"PJ Lu","year":"2021","unstructured":"Lu PJ, Hung MC, Srivastav A, Grohskopf LA, Kobayashi M, Harris AM, et al. Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. MMWR Surveill Summ. 2021;70(3):1\u201326. https:\/\/doi.org\/10.15585\/mmwr.ss7003a1. PubMed PMID: 33983910; PubMed Central PMCID: PMC8162796.","journal-title":"MMWR Surveill Summ"},{"issue":"1","key":"315_CR69","doi-asserted-by":"publisher","first-page":"taw069","DOI":"10.1093\/jtm\/taw069","volume":"24","author":"AE Heywood","year":"2016","unstructured":"Heywood AE, Nothdurft H, Tessier D, Moodley M, Rombo L, Marano C, et al. Pre-travel advice, attitudes and hepatitis A and B vaccination rates among travellers from seven countries\u2020. J Travel Med. 2016;24(1):taw069. https:\/\/doi.org\/10.1093\/jtm\/taw069.","journal-title":"J Travel Med"},{"issue":"2","key":"315_CR70","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1086\/421945","volume":"39","author":"EB Steinberg","year":"2004","unstructured":"Steinberg EB, Bishop R, Haber P, Dempsey AF, Hoekstra RM, Nelson JM, et al. Typhoid fever in travelers: who should be targeted for prevention? Clin Infect Dis. 2004;39(2):186\u201391. https:\/\/doi.org\/10.1086\/421945. PubMed PMID: 15307027.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"315_CR71","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14760584.2017.1374861","volume":"16","author":"JN Zuckerman","year":"2017","unstructured":"Zuckerman JN, Hatz C, Kantele A. Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines. Expert Rev Vaccines. 2017;16(10):1029\u201343. https:\/\/doi.org\/10.1080\/14760584.2017.1374861.","journal-title":"Expert Rev Vaccines"},{"key":"315_CR72","unstructured":"World Health Organization. Typhoid [Internet]. [cited 2026 Apr 14]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/typhoid"},{"key":"315_CR73","doi-asserted-by":"publisher","unstructured":"Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Infectious Diseases Group, editor. Cochrane Database Syst Rev. 2018;(5). https:\/\/doi.org\/10.1002\/14651858.CD001261.pub4.","DOI":"10.1002\/14651858.CD001261.pub4"},{"issue":"1","key":"315_CR74","doi-asserted-by":"publisher","first-page":"2507912","DOI":"10.1080\/21645515.2025.2507912","volume":"21","author":"KM Vadrevu","year":"2025","unstructured":"Vadrevu KM, Chiteti SR, Dugyala R, Aileni VK, Kunta Akhila, Patnaik BN, et al. Comparative immune response of Typbar TCV\u00ae (typhoid conjugate vaccine) in extremes of age: An Indian experience. Hum Vaccines Immunotherapeutics. 2025;21(1):2507912. https:\/\/doi.org\/10.1080\/21645515.2025.2507912.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"315_CR75","unstructured":"Meeting of the Strategic Advisory Group of Experts on Immunization. October 2017: conclusions and recommendations [Internet]. [cited 2026 Apr 30]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WER9247"},{"issue":"11","key":"315_CR76","doi-asserted-by":"publisher","first-page":"e0006951","DOI":"10.1371\/journal.pntd.0006951","volume":"12","author":"P Gautret","year":"2018","unstructured":"Gautret P, Angelo KM, Asgeirsson H, Lalloo DG, Shaw M, Schwartz E, et al. Rabies post-exposure prophylaxis started during or after travel: A GeoSentinel analysis. Gilbert AT. editor PLoS Negl Trop Dis. 2018;12(11):e0006951. https:\/\/doi.org\/10.1371\/journal.pntd.0006951.","journal-title":"editor PLoS Negl Trop Dis"},{"issue":"2","key":"315_CR77","doi-asserted-by":"publisher","first-page":"taab188","DOI":"10.1093\/jtm\/taab188","volume":"29","author":"DJ Mills","year":"2022","unstructured":"Mills DJ, Lau CL, Mills C, Furuya-Kanamori L. Long-term persistence of antibodies and boostability after rabies intradermal pre-exposure prophylaxis. J Travel Med. 2022;29(2):taab188. https:\/\/doi.org\/10.1093\/jtm\/taab188.","journal-title":"J Travel Med"},{"issue":"2","key":"315_CR78","doi-asserted-by":"publisher","first-page":"taaf006","DOI":"10.1093\/jtm\/taaf006","volume":"32","author":"DJ Mills","year":"2025","unstructured":"Mills DJ, Gyawali N, Nammunige NA, Mills C, Devine GJ, Lau CL, et al. Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults. J Travel Med. 2025;32(2):taaf006. https:\/\/doi.org\/10.1093\/jtm\/taaf006.","journal-title":"J Travel Med"},{"issue":"11","key":"315_CR79","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/vaccines11111683","volume":"11","author":"P Asawapaithulsert","year":"2023","unstructured":"Asawapaithulsert P, Ngamprasertchai T, Kitro A. Japanese Encephalitis vaccine acceptance and strategies for travelers: insights from a scoping review and practitioners in endemic Countries. Vaccines (Basel). 2023;11(11):1683. https:\/\/doi.org\/10.3390\/vaccines11111683.","journal-title":"Vaccines"},{"issue":"2","key":"315_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","volume":"68","author":"SL Hills","year":"2019","unstructured":"Hills SL, Walter EB, Atmar RL, Fischer M, ACIP Japanese Encephalitis Vaccine Work Group, Walter E, et al. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2019;68(2):1\u201333. https:\/\/doi.org\/10.15585\/mmwr.rr6802a1.","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"315_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7205a1","volume":"72","author":"SL Hills","year":"2023","unstructured":"Hills SL, Poehling KA, Chen WH, Staples JE. Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 2023;72(5):1\u201329. https:\/\/doi.org\/10.15585\/mmwr.rr7205a1.","journal-title":"MMWR Recomm Rep"},{"issue":"10","key":"315_CR82","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1080\/21645515.2016.1218098","volume":"12","author":"A Chrdle","year":"2016","unstructured":"Chrdle A, Chmel\u00edk V, R\u016f\u017eek D. Tick-borne encephalitis: What travelers should know when visiting an endemic country. Hum Vaccines Immunotherapeutics. 2016;12(10):2694\u20139. https:\/\/doi.org\/10.1080\/21645515.2016.1218098.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"2","key":"315_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7102a1","volume":"71","author":"JP Collins","year":"2022","unstructured":"Collins JP, Ryan ET, Wong KK, Daley MF, Ratner AJ, Appiah GD, et al. Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022. MMWR Recomm Rep. 2022;71(2):1\u20138. https:\/\/doi.org\/10.15585\/mmwr.rr7102a1.","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"315_CR84","doi-asserted-by":"publisher","first-page":"taaa052","DOI":"10.1093\/jtm\/taaa052","volume":"27","author":"R Fletcher","year":"2020","unstructured":"Fletcher R, Simons H, Patel D. Mitigating yellow-fever-vaccine-associated viscerotropic disease in older travellers. J Travel Med. 2020;27(4):taaa052. https:\/\/doi.org\/10.1093\/jtm\/taaa052.","journal-title":"J Travel Med"},{"issue":"1","key":"315_CR85","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.vaccine.2014.05.040","volume":"33","author":"Who","year":"2015","unstructured":"Who. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013\u2013recommendations. Vaccine. 2015;33(1):76\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2014.05.040. PubMed PMID: 24852721.","journal-title":"Vaccine"},{"key":"315_CR86","unstructured":"Staples JE, O\u2019Laughlin K. CDC Yellow Book: Health information for international travel [Internet]. 2025 [cited 2026 Jul 2]. Available from: https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/yellow-fever.html."},{"issue":"1","key":"315_CR87","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40794-024-00217-0","volume":"10","author":"E Beer","year":"2024","unstructured":"Beer E, Chowdhury H, Carroll B, Luintel A, Van Tulleken C, Longley N. Advising the immunocompromised traveller: a review of immunocompromise at The London Hospital for Tropical Diseases Travel Clinic between 1st April 2019 and 30th April 2020. Trop Dis Travel Med Vaccines. 2024;10(1):8. https:\/\/doi.org\/10.1186\/s40794-024-00217-0.","journal-title":"Trop Dis Travel Med Vaccines"},{"issue":"49","key":"315_CR88","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1016\/j.vaccine.2013.09.030","volume":"31","author":"E Rafferty","year":"2013","unstructured":"Rafferty E, Duclos P, Yactayo S, Schuster M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review. Vaccine. 2013;31(49):5798\u2013805. https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.030.","journal-title":"Vaccine"},{"issue":"48","key":"315_CR89","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","volume":"26","author":"NP Lindsey","year":"2008","unstructured":"Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077\u201382. https:\/\/doi.org\/10.1016\/j.vaccine.2008.09.009.","journal-title":"Vaccine"},{"issue":"25","key":"315_CR90","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","volume":"23","author":"AY Khromava","year":"2005","unstructured":"Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, et al. Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23(25):3256\u201363. https:\/\/doi.org\/10.1016\/j.vaccine.2005.01.089.","journal-title":"Vaccine"},{"issue":"5","key":"315_CR91","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3390\/vaccines10050711","volume":"10","author":"A de Abreu","year":"2022","unstructured":"de Abreu A, de JL, Cavalcante JR, de Ara\u00fajo Lagos LW, Caetano R, Braga JU. A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population. Vaccines (Basel). 2022;10(5):711. https:\/\/doi.org\/10.3390\/vaccines10050711. PubMed PMID: 35632466; PubMed Central PMCID: PMC9147422.","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"315_CR92","doi-asserted-by":"publisher","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","volume":"23","author":"NP Lindsey","year":"2016","unstructured":"Lindsey NP, Rabe IB, Miller ER, Fischer M, Staples JE. Adverse event reports following yellow fever vaccination, 2007\u201313. J Travel Med. 2016;23(5):taw045. https:\/\/doi.org\/10.1093\/jtm\/taw045.","journal-title":"J Travel Med"},{"issue":"6","key":"315_CR93","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/cid\/cis520","volume":"55","author":"BA Lown","year":"2012","unstructured":"Lown BA, Chen LH, Wilson ME, Sisson E, Gershman M, Yanni E, et al. Vaccine Administration Decision Making: The Case of Yellow Fever Vaccine. Clin Infect Dis. 2012;55(6):837\u201343. https:\/\/doi.org\/10.1093\/cid\/cis520.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"315_CR94","doi-asserted-by":"publisher","first-page":"e2021098","DOI":"10.23750\/abm.v92i4.11619","volume":"92","author":"P Ferrara","year":"2021","unstructured":"Ferrara P, Masuet-Aumatell C, Ramon-Torrell JM. Acceptance of yellow fever vaccine in the older traveller: a cohort study: Yellow fever vaccination in elderly: adherence and challenges. Acta Biomed Atenei Parmensis. 2021;92(4):e2021098. https:\/\/doi.org\/10.23750\/abm.v92i4.11619.","journal-title":"Acta Biomed Atenei Parmensis"},{"key":"315_CR95","unstructured":"Medicines and Healthcare products Regulatory Agency. GOV.UK [Internet]. 2019 [cited 2026 Apr 22]. Yellow fever vaccine: stronger precautions in people with weakened immunity and in those aged 60 years or older. Available from: https:\/\/www.gov.uk\/drug-safety-update\/yellow-fever-vaccine-stronger-precautions-in-people-with-weakened-immunity-and-in-those-aged-60-years-or-older"},{"issue":"4","key":"315_CR96","doi-asserted-by":"publisher","first-page":"taae064","DOI":"10.1093\/jtm\/taae064","volume":"31","author":"R Steffen","year":"2024","unstructured":"Steffen R, Hamer DH, Chen LH, Caumes E, Lau CL. Novel chikungunya and dengue vaccines: travel medicine applications. J Travel Med. 2024;31(4):taae064. https:\/\/doi.org\/10.1093\/jtm\/taae064.","journal-title":"J Travel Med"},{"issue":"7","key":"315_CR97","doi-asserted-by":"publisher","first-page":"taad132","DOI":"10.1093\/jtm\/taad132","volume":"30","author":"DO Freedman","year":"2023","unstructured":"Freedman DO. A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers? J Travel Med. 2023;30(7):taad132. https:\/\/doi.org\/10.1093\/jtm\/taad132.","journal-title":"J Travel Med"},{"key":"315_CR98","unstructured":"European Medicines Agency. Qdenga powder and solvent for solution for injection; Qdenga powder and solvent for solution for injection in pre-filled syringe: dengue tetravalent vaccine (live, attenuated) [Internet]. 2022 [cited 2026 Apr 17]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/qdenga-epar-product-information_en.pdf"},{"issue":"1","key":"315_CR99","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40794-024-00231-2","volume":"10","author":"DG Aynekulu Mersha","year":"2024","unstructured":"Aynekulu Mersha DG, Van Der Sterren I, Van Leeuwen LPM, Langerak T, Hakim MS, Martina B, et al. The role of antibody-dependent enhancement in dengue vaccination. Trop Dis Travel Med Vaccines. 2024;10(1):22. https:\/\/doi.org\/10.1186\/s40794-024-00231-2.","journal-title":"Trop Dis Travel Med Vaccines"},{"issue":"18","key":"315_CR100","first-page":"203","volume":"99","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. WHO position paper on dengue vaccines. Wkly Epidemiol Record - May 2024. 2024;99(18):203\u201324.","journal-title":"Wkly Epidemiol Record - May 2024"},{"key":"315_CR101","doi-asserted-by":"publisher","first-page":"102598","DOI":"10.1016\/j.tmaid.2023.102598","volume":"54","author":"M Angelin","year":"2023","unstructured":"Angelin M, Sj\u00f6lin J, Kahn F, Ljunghill Hedberg A, Rosdahl A, Skorup P, et al. Qdenga\u00ae - A promising dengue fever vaccine; can it be recommended to non-immune travelers? Travel Med Infect Dis. 2023;54:102598. https:\/\/doi.org\/10.1016\/j.tmaid.2023.102598.","journal-title":"Travel Med Infect Dis"},{"key":"315_CR102","doi-asserted-by":"publisher","unstructured":"Simone B, Lienert F Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025. Eurosurveillance. 2025;30(44). https:\/\/doi.org\/10.2807\/1560-7917.ES.2025.30.44.2500792.","DOI":"10.2807\/1560-7917.ES.2025.30.44.2500792"},{"issue":"7","key":"315_CR103","doi-asserted-by":"publisher","first-page":"taae084","DOI":"10.1093\/jtm\/taae084","volume":"31","author":"V Buerger","year":"2024","unstructured":"Buerger V, Maurer G, Kosulin K, Hochreiter R, Larcher-Senn J, Dubischar K, et al. Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine. J Travel Med. 2024;31(7):taae084. https:\/\/doi.org\/10.1093\/jtm\/taae084.","journal-title":"J Travel Med"},{"key":"315_CR104","doi-asserted-by":"publisher","unstructured":"Hills SL, Sutter RA, Miller ER, Asturias EJ, Chen LH, Bell BP, et al. Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025. Euro Surveill. 2025;30(32). https:\/\/doi.org\/10.2807\/1560-7917.ES.2025.30.32.2500543.","DOI":"10.2807\/1560-7917.ES.2025.30.32.2500543"},{"issue":"5","key":"315_CR105","doi-asserted-by":"publisher","first-page":"taaf039","DOI":"10.1093\/jtm\/taaf039","volume":"32","author":"DO Freedman","year":"2025","unstructured":"Freedman DO. A new non-live chikungunya vaccine for travellers. J Travel Med. 2025;32(5):taaf039. https:\/\/doi.org\/10.1093\/jtm\/taaf039.","journal-title":"J Travel Med"},{"issue":"10487","key":"315_CR106","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(25)00372-1","volume":"405","author":"LC Tindale","year":"2025","unstructured":"Tindale LC, Richardson JS, Anderson DM, Mendy J, Muhammad S, Loreth T, et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10487):1353\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(25)00372-1.","journal-title":"Lancet"},{"key":"315_CR107","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ijid.2018.04.4185","volume":"73","author":"P Oses","year":"2018","unstructured":"Oses P, Ariscancela M, Barney N, Nacinovich F. Pre travel consultation in individuals with chronic illnesses: perception of the risk in doctors and patients. Int J Infect Dis. 2018;73:339\u201340. https:\/\/doi.org\/10.1016\/j.ijid.2018.04.4185.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"315_CR108","doi-asserted-by":"publisher","first-page":"taz059","DOI":"10.1093\/jtm\/taz059","volume":"26","author":"D Kain","year":"2019","unstructured":"Kain D, Findlater A, Lightfoot D, Maxim T, Kraemer MUG, Brady OJ, et al. Factors Affecting Pre-Travel Health Seeking Behaviour and Adherence to Pre-Travel Health Advice: A Systematic Review. J Travel Med. 2019;26(6):taz059. https:\/\/doi.org\/10.1093\/jtm\/taz059.","journal-title":"J Travel Med"},{"key":"315_CR109","doi-asserted-by":"publisher","first-page":"102842","DOI":"10.1016\/j.tmaid.2025.102842","volume":"65","author":"A Bogacka","year":"2025","unstructured":"Bogacka A, Wroczy\u0144ska A, Grzybek M. Polish travellers on the move: A study of knowledge of travel health and associated practices among polish travellers abroad. Travel Med Infect Dis. 2025;65:102842. https:\/\/doi.org\/10.1016\/j.tmaid.2025.102842.","journal-title":"Travel Med Infect Dis"},{"key":"315_CR110","doi-asserted-by":"publisher","first-page":"101579","DOI":"10.1016\/j.tmaid.2020.101579","volume":"34","author":"EKK Fong","year":"2020","unstructured":"Fong EKK, Pell LG, Faress A, Nguyen JH, Ma XW, Lam RE, et al. Adherence to recommendations at a Canadian tertiary care Family Travel Clinic - A single centre analysis. Travel Med Infect Dis. 2020;34:101579. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101579.","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"315_CR111","doi-asserted-by":"publisher","first-page":"taw078","DOI":"10.1093\/jtm\/taw078","volume":"24","author":"M Goeijenbier","year":"2017","unstructured":"Goeijenbier M, Van Genderen P, Ward BJ, Wilder-Smith A, Steffen R, Osterhaus ADME. Travellers and influenza: risks and prevention. J Travel Med. 2017;24(1):taw078. https:\/\/doi.org\/10.1093\/jtm\/taw078.","journal-title":"J Travel Med"},{"issue":"3","key":"315_CR112","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1708-8305.2012.00613.x","volume":"19","author":"P Gautret","year":"2012","unstructured":"Gautret P, Gaudart J, Leder K, Schwartz E, Castelli F, Lim PL, et al. Travel-Associated Illness in Older Adults (>\u200960 y). J Travel Med. 2012;19(3):169\u201377. https:\/\/doi.org\/10.1111\/j.1708-8305.2012.00613.x.","journal-title":"J Travel Med"},{"issue":"10267","key":"315_CR113","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/S0140-6736(20)32481-8","volume":"396","author":"MK Andrew","year":"2020","unstructured":"Andrew MK, McElhaney JE. Age and frailty in COVID-19 vaccine development. Lancet. 2020;396(10267):1942\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(20)32481-8.","journal-title":"Lancet"},{"issue":"2","key":"315_CR114","doi-asserted-by":"publisher","first-page":"taaf004","DOI":"10.1093\/jtm\/taaf004","volume":"32","author":"C K\u00f6pke","year":"2025","unstructured":"K\u00f6pke C, Rothe C, Zeder A, Boecken G, Feldt T, Janke C, et al. First clinical experiences with the tetravalent live vaccine against dengue (Qdenga\u00ae) in travellers: a multicentric TravVacNet study in Germany. J Travel Med. 2025;32(2):taaf004. https:\/\/doi.org\/10.1093\/jtm\/taaf004.","journal-title":"J Travel Med"},{"issue":"8","key":"315_CR115","doi-asserted-by":"publisher","first-page":"taab126","DOI":"10.1093\/jtm\/taab126","volume":"28","author":"MD Rosenstein","year":"2021","unstructured":"Rosenstein MD, De Visser AW, Visser LG, Roukens AHE. Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: A 10-year follow-up study. J Travel Med. 2021;28(8):taab126. https:\/\/doi.org\/10.1093\/jtm\/taab126.","journal-title":"J Travel Med"},{"key":"315_CR116","doi-asserted-by":"publisher","unstructured":"Pillet S, Couillard J, Tr\u00e9panier S, Poulin JF, Yassine-Diab B, Guy B et al. Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate\u2014Two randomized Phase II clinical trials in 18 to 49 and \u2265\u200950 years old adults. Borrow R, editor. PLoS ONE. 2019;14(6):e0216533. https:\/\/doi.org\/10.1371\/journal.pone.0216533","DOI":"10.1371\/journal.pone.0216533"}],"container-title":["Tropical Diseases, Travel Medicine and Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40794-026-00315-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-026-00315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-026-00315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:21:17Z","timestamp":1789460477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40794-026-00315-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1186\/s40794-026-00315-1","relation":{},"ISSN":["2055-0936"],"issn-type":[{"value":"2055-0936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"33"}}